Page 224 - 2021_12-Haematologica-web

Letters to the Editor
Squibb, Pfizer, and Sunesis. HD reports grants and personal fees from Celgene, Amgen, Incyte, Novartis, Jazz Pharmaceuticals, Daiichi Sankyo, Servier, and Astellas; and personal fees from Pfizer, Cellectis, Menarini, Otsuka, AbbVie, Janssen, Shire-Baxalta, Celyad, Agios, and Immunogen. FR reports honoraria and consulting fees from Bristol Myers Squibb and Celgene; and research funding from Bristol Myers Squibb. DS reports honoraria from Novartis, Celgene, Amgen, Janssen-Cilag, AbbVie, Alexion, GSK, MSD, Pfizer, Sanofi , Takeda, Incyte, and Teva; consultancy for Novartis, Celgene, Amgen, Janssen-Cilag, AbbVie, Alexion, GSK, MSD, Pfizer, Sanofi, Takeda, Incyte, and Teva; and speakers’ bureau participation for Novartis, Celgene, Amgen, MSD, Takeda, and Teva. JM reports research funding from Celgene. UMM reports consultancy for Bristol Myers Squibb, Merck, Amgen, Roche, and Celgene; and travel accommoda- tions/expenses from Bristol Myers Squibb, Amgen, Pierre-Fabre, and Celgene. JL reports participation in DSMB for Onconova. PY, LS, and SG are employed by Evidera. BS is employed by Bristol Myers Squibb. ILT, QD, JB, SAN, and CLB are employed at and have equity ownership in Bristol Myers Squibb. AHW reports study-related fees and personal fees from Celgene; royalties from Walter and Eliza Hall Institute of Medical Research; grants from the Medical Research Future Fund; grants and personal fees from Servier, AbbVie, Novartis, Celgene, Astra Zeneca, and Janssen; and personal fees from Astellas, Pfizer, Macrogenics, and Amgen. CP, JHJ, TB, and MCW report no conflicts of interest.
Contributions: the sponsors collected and analyzed data in conjunc- tion with all authors. The lead author wrote the initial draft of the man- uscript. All authors revised the manuscript and reviewed and approved the final version for submission.
Acknowledgments: additional support on an early draft of the manuscript was provided by Sheila Truten and Brian Kaiser from Medical Communication Company, Inc. (Wynnewood, PA, USA), funded by Bristol Myers Squibb and in accordance with Good Publication Practice guidelines
Funding: this study was sponsored and funded by Celgene, a Bristol-Myers Squibb Company.
Data sharing statement: BMS policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent- research/data-sharing-request-process.html
References
1. Brandwein JM, Saini L, Geddes MN, et al. Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study. Am J Blood Res. 2020;10(4):124-133.
2. Wei A, Dohner H, Pocock C, et al. Oral azacitidine maintenance for acute myeloid leukemia in first remission. N Engl J Med. 2020; 383(26):2526-2537.
3. Alibhai SM, Breunis H, Timilshina N, et al. Quality of life and phys- ical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. J Geriatr Oncol. 2015;6(4):262-271.
4. Timilshina N, Breunis H, Tomlinson GA, et al. Long-term recovery of quality of life and physical function over three years in adult sur- vivors of acute myeloid leukemia after intensive chemotherapy. Leukemia. 2019;33(1):15-25.
5. Gerlinger C, Schmelter T. Determining the non-inferiority margin for patient reported outcomes. Pharm Stat. 2011;10(5):410-413.
6.Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J, Epoetin Alfa Study G. Assessing the clinical significance of health- related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003;39(3):335-345.
7. Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal impor- tant score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87(4):330-337.
8. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
9. Ashbeck EL, Bell ML. Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of miss- ing data. BMC Med Res Methodol. 2016;16:43.
10. U.S. Department of Health and Human Services - Food and Drug Administration. Non-inferiority clinical trials to establish effective- ness: guidance for industry. In: Services UDoHaH, ed, 2016.
11. Montan I, Lowe B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. Value Health. 2018;21(11):1313-1321.
12.Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D [Internet]. Dordrecht (NL): Springer, 2014.
13. National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML). [cited March 1, 2021]; Available from: https://seer.cancer.gov/statfacts/html/amyl.html.
3244
haematologica | 2021; 106(12)